BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Muga R. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 2009;16:513-8. [PMID: 19200132 DOI: 10.1111/j.1365-2893.2009.01103.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Rodart IF, Pares MM, Mendes A, Accardo CM, Martins JRM, Silva CB, Carvalho FO, Barreto JA, Reis MG, Tersariol ILS, Nader HB. Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors. Molecules 2021;26:3892. [PMID: 34202190 DOI: 10.3390/molecules26133892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Solomennyk GO, Bondar OY, Antsyferova NV, Gavrylov AV. METABOLISM FEATURES OF HAPTOGLOBIN AS INFLAMMATION ACUTE PHASE PROTEIN IN PATIENTS WITH CHRONIC HCV INFECTION. IMJ 2020. [DOI: 10.37436/2308-5274-2020-2-14] [Reference Citation Analysis]
3 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Sanvisens A, Muñoz A, Bolao F, Zuluaga P, Farré M, Jarrin I, Tor J, Muga R. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder? Drug Alcohol Depend 2018;188:180-6. [PMID: 29778771 DOI: 10.1016/j.drugalcdep.2018.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Sherman KE, Sterling RK. HIV and the Liver. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00037-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
7 Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016;89:24-31. [PMID: 27004022 DOI: 10.15386/cjmed-554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
8 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 12.0] [Reference Citation Analysis]
9 Nassef YE, Shady MM, Galal EM, Hamed MA. Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children. Mem Inst Oswaldo Cruz 2013;108:887-93. [PMID: 24141960 DOI: 10.1590/0074-0276130139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
10 Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One. 2013;8:e64283. [PMID: 23724041 DOI: 10.1371/journal.pone.0064283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
11 Muga R, Sanvisens A, Fuster D, Tor J, Martínez E, Pérez-Hoyos S, Muñoz A. Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One 2012;7:e46810. [PMID: 23056462 DOI: 10.1371/journal.pone.0046810] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
12 Peters L, Neuhaus J, Mocroft A, Soriano V, Rockstroh J, Dore G, Puoti M, Tedaldi E, Clotet B, Kupfer B, Lundgren JD, Klein MB; SMART Study Group. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther 2011;16:667-75. [PMID: 21817188 DOI: 10.3851/IMP1815] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Tor J, Muga R. [Evaluation of liver fibrosis by non-invasive methods]. Med Clin (Barc) 2011;137:642-4. [PMID: 21752404 DOI: 10.1016/j.medcli.2011.05.002] [Reference Citation Analysis]
14 Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6:e23218. [PMID: 21858035 DOI: 10.1371/journal.pone.0023218] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
15 Macías J, Mira J, Gilabert I, Neukam K, Roldán C, Viloria M, Moro A, Pineda JA. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2011;12:14-21. [PMID: 20497249 DOI: 10.1111/j.1468-1293.2010.00836.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
17 Rallón NI, Barreiro P, Soriano V, García-Samaniego J, López M, Benito JM. Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis. Eur J Clin Invest 2011;41:70-6. [PMID: 20868448 DOI: 10.1111/j.1365-2362.2010.02381.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
18 Mu X, Bellayr I, Walters T, Li Y. Mediators leading to fibrosis - how to measure and control them in tissue engineering. Oper Tech Orthop 2010;20:110-8. [PMID: 20890400 DOI: 10.1053/j.oto.2009.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]